Yahoo
    OTC Markets OTCPK USD

    Chugai Pharmaceutical Co., Ltd. (CHGCY)

    21.66 +0.51 (+2.41%)
    At close: October 30 at 4:00:00 PM EDT
    Loading Chart for CHGCY
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Chugai Pharmaceutical (TSE:4519) Stock Price Trails Strong Q3 Earnings

    Chugai Pharmaceutical (TSE:4519) Stock Price Trails Strong Q3 Earnings
    Simply Wall St. 3d ago
    Chugai expects full-year results to beat forecast as drug exports and royalties gr

    Chugai expects full-year results to beat forecast as drug exports and royalties gr
    Investing.com 5d ago
    Chugai Pharmaceutical (TSE:4519) Stock May Be Cheap On Cash Flow

    Chugai Pharmaceutical (TSE:4519) Stock May Be Cheap On Cash Flow
    Simply Wall St. 7d ago
    Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

    Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
    MarketBeat 10d ago
    Will Regaining Emugrobart Rights and Refocusing on SMA Change Chugai Pharmaceutical's (TSE:4519) Narrative

    Will Regaining Emugrobart Rights and Refocusing on SMA Change Chugai Pharmaceutical's (TSE:4519) Narrative
    Simply Wall St. 26d ago
    Oil Bills, Bond Yields, Tech Jitters Damp Asian Stock Markets

    Oil Bills, Bond Yields, Tech Jitters Damp Asian Stock Markets
    PREMIUM
    MT Newswires 1mo ago
    Chugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Own

    Chugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Own
    Simply Wall St. 1mo ago
    Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

    Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
    Business Wire 1mo ago
    Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight

    Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
    PR Newswire 1mo ago
    3 Japanese AI Healthcare Stocks Investors May Want To Watch

    3 Japanese AI Healthcare Stocks Investors May Want To Watch
    Simply Wall St. 2mo ago
    RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors

    RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors
    GlobeNewswire 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: